Transgene (0OCQ) AI Stock Analysis

Transgene

(LSE:0OCQ)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Low leverage and substantial equity baseVery low leverage provides Transgene with greater financial flexibility than a heavily indebted biotech and limits near-term balance-sheet pressure. The sizable equity base can help support continued development activity, although its effectiveness depends on the company’s ability to control ongoing losses and cash usage.

Negative Factors

Persistent losses and deeply negative marginsPersistent losses and severely negative margins show that the current cost base is not supported by revenue, leaving profitability dependent on future clinical or commercial progress. Without sustained revenue growth or cost reduction, negative earnings can continue to consume capital and weaken shareholder returns.

Transgene (0OCQ) vs. iShares MSCI United Kingdom ETF (EWC)

Market Cap: EUR 104.40M
Dividend Yield: ―
Average Volume (3M): 2,004
Price to Earnings (P/E): -4.3
Beta (1Y): 0.21
Revenue Growth: 189.81%
EPS Growth: 38.50%
Country: UK
Employees: 152
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Transgene Business Overview & Revenue Model

Company Description

Transgene SA, a French biotechnology firm headquartered in Illkirch-Graffenstaden, specializes in designing and developing groundbreaking therapeutic vaccines and oncolytic viruses to combat cancer and infectious diseases. Founded in 1979 and operati...

Transgene Earnings Call Summary

Earnings Call Date:Mar 23, 2026(Q4-2025)|% Change Since:-2.95%|Next Earnings Date:May 12, 2019

Earnings Call SentimentPositive

The call emphasized several strong positives: robust fundraising (EUR 105M), a strengthened balance sheet (EUR 39M debt conversion), compelling Phase I efficacy and durable immunogenicity signals for TG4050 (100% disease-free in treated Phase I patients; 73% immunogenicity with responses persisting 24 months), encouraging BT-001 combination data, and a clear plan for manufacturing and regulatory readiness. Counterbalancing these highlights are timing and operational risks (GMP readiness targeted Q3 2027), immature/pending pivotal readouts (Phase II 2-year DFS not yet available), ongoing cash burn (~EUR 38.2M in 2025) and some dependence on broader field validation. Overall, the positive clinical signals and strengthened financial position outweigh the execution and timing risks at this stage.

Positive Updates

Successful Fundraising and Balance Sheet Strengthening

Raised approximately EUR 105 million in December 2025 and converted EUR 39 million of debt into equity, leaving the company virtually debt-free and providing financial visibility/runway through early 2028.

Negative Updates

Key Efficacy Readouts Not Yet Mature or Fully Peer-Reviewed

Primary efficacy readout for Phase I/II (2-year DFS for Phase II) is pending until patients reach 2 years post-randomization; Phase I comprehensive analysis is currently a preprint under peer review, so data are not yet fully validated by peer-reviewed publication.

Company Guidance

The call laid out clear, metric-driven guidance: Transgene raised ~EUR 105m in December 2025 and converted ~EUR 39m of debt to equity (now virtually debt‑free), giving cash visibility through early 2028 (first quarter 2028) after a 2025 cash burn of ~EUR 38.2m; clinically, the primary endpoint for the randomized Phase I/II TG4050 study is 2‑year disease‑free survival (DFS) with an efficacy readout once all patients reach 2 years, Phase I 3‑year DFS data expected Q2–Q3 2026 and 4‑year follow‑up Q2–Q3 2027, Phase II patient randomization to be completed by Q2 2026 and first Phase II immunogenicity data in H2 2026 (with ~1 year follow‑up possible), and Phase I translational results showed 100% DFS at ≥2 years in treated HPV‑negative HNSCC patients vs. 3 relapses in controls and neoantigen‑specific T‑cell responses in 73% of evaluable patients that persisted 24 months; manufacturing and regulatory investments target full GMP capacity by Q3 2027 and a second Phase I indication is slated to start in 2026.

Transgene Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

GB:0OCQ against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
FR:IPH	47Neutral	EUR 140.30M	-2.46	152.56%	―	-29.48%	7.91%
FR:NANO	46Neutral	EUR 1.43B	-25.56	89.71%	―	―	―
FR:OSE	43Neutral	EUR 45.93M	-1.16	-96.73%	―	-96.25%	-197.89%
FR:ALCLS	43Neutral	EUR 75.07M	-1.78	-94.14%	―	-5.98%	-8.67%
FR:MAAT	39Underperform	EUR 19.20M	-0.53	―	―	-19.02%	10.39%

* Healthcare Sector Average

Performance Comparison

GB:0OCQ and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
GB:0OCQ	Transgene SA	0.72	-0.63	-46.37%
FR:IPH	Innate Pharma S.A.	1.26	-0.39	-23.51%
FR:NANO	Nanobiotix SA	28.12	12.36	78.43%
FR:OSE	OSE Immunotherapeutics	1.95	-3.75	-65.75%
FR:ALCLS	Cellectis SA	1.04	-1.90	-64.63%
FR:MAAT	MaaT Pharma	1.02	-3.25	-76.16%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Transgene AI Stock Analysis